WO2005100556A3 - Cleavage of vegf and vegf receptor by wild-type and mutant proteases - Google Patents

Cleavage of vegf and vegf receptor by wild-type and mutant proteases Download PDF

Info

Publication number
WO2005100556A3
WO2005100556A3 PCT/US2005/012243 US2005012243W WO2005100556A3 WO 2005100556 A3 WO2005100556 A3 WO 2005100556A3 US 2005012243 W US2005012243 W US 2005012243W WO 2005100556 A3 WO2005100556 A3 WO 2005100556A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
wild
type
cleavage
mutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/012243
Other languages
French (fr)
Other versions
WO2005100556A2 (en
Inventor
Sandra Waugh Ruggles
Jack Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gyre Therapeutics Inc
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Priority to EP05735778A priority Critical patent/EP1735438A2/en
Publication of WO2005100556A2 publication Critical patent/WO2005100556A2/en
Publication of WO2005100556A3 publication Critical patent/WO2005100556A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Disclosed herein are methods for creating and using mutein proteases with altered specificity for the target molecules they cleave. The invention further discloses methods of using wild-type and mutein granzyme B to target VEGFR proteins to treat diseases, such as cancer. Cleaving VEGFR at certain substrate sequences with wild-type and mutein granzyme B proteases is a method for treating pathologies associated with angiogenesis.
PCT/US2005/012243 2004-04-12 2005-04-12 Cleavage of vegf and vegf receptor by wild-type and mutant proteases Ceased WO2005100556A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05735778A EP1735438A2 (en) 2004-04-12 2005-04-12 Cleavage of vegf and vegf receptor by wild-type and mutant proteases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56167104P 2004-04-12 2004-04-12
US60/561,671 2004-04-12

Publications (2)

Publication Number Publication Date
WO2005100556A2 WO2005100556A2 (en) 2005-10-27
WO2005100556A3 true WO2005100556A3 (en) 2006-01-19

Family

ID=35150553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/012243 Ceased WO2005100556A2 (en) 2004-04-12 2005-04-12 Cleavage of vegf and vegf receptor by wild-type and mutant proteases

Country Status (2)

Country Link
EP (1) EP1735438A2 (en)
WO (1) WO2005100556A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290757B2 (en) 2006-07-05 2016-03-22 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
US9359598B2 (en) 2004-04-12 2016-06-07 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
US11266724B2 (en) 2019-08-15 2022-03-08 Catalyst Biosciences, Inc. Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2433642B1 (en) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
AT504159A1 (en) 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc USE OF PROTEASES
TWI465247B (en) 2008-04-11 2014-12-21 Catalyst Biosciences Inc Modified Factor VII polypeptide and use thereof
EP2758527B1 (en) 2011-09-23 2016-11-09 PharmedArtis GmbH Novel serine protease variants
CN111670250B (en) * 2017-12-21 2024-02-13 生化酶股份有限公司 Variants of fungal cellulases
WO2021241719A1 (en) * 2020-05-28 2021-12-02 中外製薬株式会社 Improved granzyme b variant
CN111944790B (en) * 2020-07-01 2022-09-09 深圳润康生态环境股份有限公司 Neutral protease gene, neutral protease, preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022243A1 (en) * 2000-06-02 2002-02-21 Harris Jennifer L. Profiling of protease specificity using combinatorial fluorogenic substrate libraries
WO2004031733A2 (en) * 2002-10-02 2004-04-15 Catalyst Biosciences Methods of generating and screenign for porteases with altered specificity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022243A1 (en) * 2000-06-02 2002-02-21 Harris Jennifer L. Profiling of protease specificity using combinatorial fluorogenic substrate libraries
WO2004031733A2 (en) * 2002-10-02 2004-04-15 Catalyst Biosciences Methods of generating and screenign for porteases with altered specificity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRIEDRICH R ET AL: "Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 3, 18 January 2002 (2002-01-18), pages 2160 - 2168, XP002244714, ISSN: 0021-9258 *
HARRIS J L ET AL: "Definition and redesign of the extended substrate specificity of granzyme B", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 273, no. 42, 16 October 1998 (1998-10-16), pages 27364 - 27373, XP002296677, ISSN: 0021-9258 *
RUGGLES SANDRA WAUGH ET AL: "Characterization of structural determinants of granzyme B reveals potent mediators of extended substrate specificity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 279, no. 29, 16 July 2004 (2004-07-16), pages 30751 - 30759, XP002304824, ISSN: 0021-9258 *
WAUGH S M ET AL: "The structure of the pro-apoptotic protease granzyme B reveals the molecular determinants of its specificity", NATURE STRUCTURAL BIOLOGY, NEW YORK, NY, US, vol. 7, no. 9, September 2000 (2000-09-01), pages 762 - 765, XP002307284, ISSN: 1072-8368 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359598B2 (en) 2004-04-12 2016-06-07 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
US9290757B2 (en) 2006-07-05 2016-03-22 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
US11266724B2 (en) 2019-08-15 2022-03-08 Catalyst Biosciences, Inc. Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Also Published As

Publication number Publication date
WO2005100556A2 (en) 2005-10-27
EP1735438A2 (en) 2006-12-27

Similar Documents

Publication Publication Date Title
WO2005110453A3 (en) Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
WO2004031733A3 (en) Methods of generating and screenign for porteases with altered specificity
WO2005100556A3 (en) Cleavage of vegf and vegf receptor by wild-type and mutant proteases
WO2011036640A3 (en) Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
WO2004013280A3 (en) ALLELE-SPECIFIC siRNA-MEDIATED GENE SILENCING
WO2006015124A3 (en) Fused ring heterocycle kinase modulators
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2006060419A3 (en) Biomarkers for pre-selection of patients for anti-igf1r therapy
HUP0300369A2 (en) Multivalent antibodies and uses therefor
WO2007002904A3 (en) Methods and sequences to preferentially suppress expression of mutated huntingtin
WO2001071009A3 (en) Whole-body optical imaging of gene expression and uses thereof
LT2012062A (en) Compositions, methods and related uses for cleaving modified dna
WO2006068794A3 (en) Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
EP1947180A4 (en) TRANSGENIC SILKWORM CAPABLE OF PRODUCING ANTIBODY AND METHOD FOR PRODUCING THE SAME
WO2005058945A3 (en) Gene variants coding for proteins from the metabolic pathway of fine chemicals
WO2005086768A3 (en) Enhanced production of functional proteins from defective genes
WO2003004628A3 (en) Method for purifying an enzyme, a purified enzyme produced thereby, and use of this enzyme
WO2006063055A3 (en) Enzyme conjugates for use as detoxifying agents
WO2005069913A3 (en) Expression of mammalian proteins in pseudomonas fluorescens
WO2003064622A3 (en) Aggrecanase molecules
WO2005074655A3 (en) Materials and method for promotion of nerve regeneration
ATE535530T1 (en) 7-SUBSTITUTED CAMPTOTHECINE AND CAMPTOTHECINE ANALOGAS AND PRODUCTION PROCESS THEREOF
WO2004007670A3 (en) RECOMBINANT TYPE II RESTRICTION ENDONUCLEASES, MmeI AND RELATED ENDONUCLEASES AND METHODS FOR PRODUCTING THE SAME
WO2003012116A3 (en) Caax prenyl protease nucleic acids and polypeptides and methods of use thereof
Simkus et al. Correlation between recombinase activating gene 1 ubiquitin ligase activity and V (D) J recombination

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005735778

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005735778

Country of ref document: EP